Literature DB >> 33328603

Optimal dosing of cytarabine in induction and post-remission therapy of acute myeloid leukemia.

Roland B Walter1,2,3,4, Frederick R Appelbaum5,6, Elihu H Estey5,7.   

Abstract

Entities:  

Year:  2020        PMID： 33328603     DOI： 10.1038/s41375-020-01110-3

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

1.  Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.

Authors:  J W Yates; H J Wallace; R R Ellison; J F Holland
Journal:  Cancer Chemother Rep       Date:  1973 Nov-Dec

2.  [A new agent active in the treatment of acute leukemia: cytosine arabinoside].

Authors:  J Bernard; M Boiron; C Jacquillat; M Weil; Y Najean
Journal:  Presse Med       Date:  1966-03-26       Impact factor: 1.228

3.  Saturation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy.

Authors:  W Plunkett; J O Liliemark; T M Adams; B Nowak; E Estey; H Kantarjian; M J Keating
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

4.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Authors:  C D Bloomfield; D Lawrence; J C Byrd; A Carroll; M J Pettenati; R Tantravahi; S R Patil; F R Davey; D T Berg; C A Schiffer; D C Arthur; R J Mayer
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701
  4 in total
  2 in total

1.  Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.

Authors:  Lijie Han; Yilu Li; Jiaying Wu; Jie Peng; Xiaolin Han; Hongmian Zhao; Chen He; Yuanyuan Li; Weimin Wang; Mengmeng Zhang; Yafei Li; Hui Sun; Haixia Cao; Li'na Sang; Zhongxing Jiang; Jifeng Yu
Journal:  Int J Hematol       Date:  2022-08-28       Impact factor: 2.319

2.  Targeting autophagy peptidase ATG4B with a novel natural product inhibitor Azalomycin F4a for advanced gastric cancer.

Authors:  Lin Zhong; Bin Yang; Zhenhua Zhang; Junfeng Wang; Xiaojuan Wang; Yinfeng Guo; Weifeng Huang; Qianqian Wang; Guodi Cai; Fan Xia; Shengning Zhou; Shuai Ma; Yichu Nie; Jinping Lei; Min Li; Peiqing Liu; Wenbin Deng; Yonghong Liu; Fanghai Han; Junjian Wang
Journal:  Cell Death Dis       Date:  2022-02-18       Impact factor: 8.469
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.